https://www.synabs.be/ https://www.synabs.be/about-synabs/ https://www.synabs.be/rat-monoclonal-antibodies/ https://www.synabs.be/welcome-to-singular-mab-experience/synabs-gender-equality-plan/ https://www.synabs.be/welcome-to-singular-mab-experience/synabs-quality-policy/ https://www.synabs.be/welcome-to-singular-mab-experience/synabs-sales-policy/ https://www.synabs.be/custom-monoclonal-antibody-development/ https://www.synabs.be/custom-monoclonal-antibody-development/transmembrane-proteins-antibodies/ https://www.synabs.be/custom-monoclonal-antibody-development/carbohydrate-specific-antibodies/ https://www.synabs.be/rat-monoclonal-antibodies/unique-mabs-targeting-dna-epigenetic-modifications/ https://www.synabs.be/rat-monoclonal-antibodies/therapeutic-anti-il34-mabs/ https://www.synabs.be/rat-monoclonal-antibodies/unique-mabs-targeting-peptide-biomarkers/ https://www.synabs.be/rat-monoclonal-antibodies/singular-mabs-for-infectious-diseases-antigens/ https://www.synabs.be/rat-monoclonal-antibodies/high-affinity-mabs-against-steroids/ https://www.synabs.be/rat-monoclonal-antibodies/high-sensitivity-anti-aflatoxin-mabs/ https://www.synabs.be/primary-monoclonal-antibodies/ https://www.synabs.be/primary-monoclonal-antibodies/primary-monoclonal-antibodies-irrelevant-ig-anti-dnp/ https://www.synabs.be/primary-monoclonal-antibodies/anti-gpcr-antibodies/ https://www.synabs.be/primary-monoclonal-antibodies/anti-histone-epigenetic-modification-antibodies/ https://www.synabs.be/primary-monoclonal-antibodies/anti-mmp9-il1b-antibodies/ https://www.synabs.be/primary-monoclonal-antibodies/primary-monoclonal-antibodies-negative-control-ig/ https://www.synabs.be/primary-monoclonal-antibodies/primary-monoclonal-antibodies-anti-his-tag/ https://www.synabs.be/primary-monoclonal-antibodies/primary-monoclonal-antibodies-anti-steroids/ https://www.synabs.be/primary-monoclonal-antibodies/primary-monoclonal-antibodies-anti-cytokines-anti-hormones/ https://www.synabs.be/primary-monoclonal-antibodies/anti-hemoglobin-antibodies/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-mouse-ig/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-mouse-ig/rat-anti-mouse-iga-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-mouse-ig/rat-anti-mouse-igd-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-mouse-ig/rat-anti-mouse-ige-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-mouse-ig/rat-anti-mouse-igg1-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-mouse-ig/rat-anti-mouse-igg2a-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-mouse-ig/rat-anti-mouse-igg2b-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-mouse-ig/rat-anti-mouse-igg3-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-mouse-ig/rat-anti-mouse-igg-total-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-mouse-ig/rat-anti-mouse-igm-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-mouse-ig/rat-anti-mouse-kappa-light-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/mouse-anti-rat-iga-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/mouse-anti-rat-igd-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/mouse-anti-rat-ige-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/mouse-anti-rat-igg1-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/mouse-anti-rat-igg2a-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/mouse-anti-rat-igg2b-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/mouse-anti-rat-igg2c-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/mouse-anti-rat-igg-total-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/mouse-anti-rat-igm-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/mouse-anti-rat-kappa-light-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/mouse-anti-rat-lambda-light-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-rat-ig/mouse-anti-rat-kappa-lambda-light-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-human-ig/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-human-ig/rat-anti-human-iga-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-human-ig/rat-anti-human-igd-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-human-ig/rat-anti-human-ige-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-human-ig/rat-anti-human-igg4-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-human-ig/rat-anti-human-igg-total-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-human-ig/rat-anti-human-igm-heavy-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-human-ig/rat-anti-human-kappa-light-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-human-ig/rat-anti-human-lambda-light-chain/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-species-mabs-1/ https://www.synabs.be/our-antibody-products/secondary-monoclonal-antibodies-anti-species-mabs/ https://www.synabs.be/immunoassays-provider/immunoaffinity-columns/ https://www.synabs.be/synabs-recent-news/ https://www.synabs.be/synabs-recent-news/gpcr-therapeutic-monoclonal-antibodies/ https://www.synabs.be/synabs-recent-news/ion-channel-therapeutic-monoclonal-antibodies/ https://www.synabs.be/synabs-recent-news/monoclonal-antibody-targeting-virus-envelope/ https://www.synabs.be/synabs-recent-news/epigenetics-and-monoclonal-histone-modification-antibodies/ https://www.synabs.be/synabs-recent-news/anti-drug-antibody-ada-generation/ https://www.synabs.be/synabs-recent-news/anti-small-molecule-hapten-antibodies/ https://www.synabs.be/synabs-recent-news/recombinant-antibodies/ https://www.synabs.be/synabs-recent-news/secondary-monoclonal-antibodies/ https://www.synabs.be/about-synabs/synabs-recent-news/technical-breakthrough/ https://www.synabs.be/synabs-recent-news/microbiome-cell-gene-therapy/ https://www.synabs.be/synabs-recent-news/receptor-tyrosine-kinase-therapeutic-monoclonal-antibodies/ https://www.synabs.be/synabs-recent-news/immunoglobulin-superfamily-igsf-therapeutic-antibodies/ https://www.synabs.be/about-synabs/contact-synabs/ https://www.synabs.be/about-synabs/glossary-and-frequently-asked-questions/ https://www.synabs.be/2026/05/07/transforming-legacy-monoclonal-antibodies-into-cynomolgus-compatible-recombinant-controls-the-lo-hk-3-case-study/ https://www.synabs.be/2026/04/28/high-quality-antibodies-for-varicella-zoster-virus-vzv-vaccine-quality-control-addressing-traceability-and-reproducibility-challenges-in-ruo-reagents/ https://www.synabs.be/2026/02/26/monoclonal-antibodies-for-hemoglobin-e-hbe-detection-and-variant-level-discrimination/ https://www.synabs.be/2026/02/26/monoclonal-antibodies-for-hemoglobin-a-hba-detection-and-hemoglobin-variant-discrimination/ https://www.synabs.be/2026/02/26/monoclonal-antibodies-for-hemoglobin-c-hbc-detection-and-variant-level-discrimination/ https://www.synabs.be/2026/02/26/monoclonal-antibodies-for-hemoglobin-s-hbs-detection-and-variant-discrimination/ https://www.synabs.be/2025/05/13/decoding-mrsa-monoclonal-antibody-innovation-targeting-pbp2a-and-pbp2b/ https://www.synabs.be/2025/07/02/mark-a-versatile-tool-for-rat-antibody-detection-control-line-capture-and-ig-purification/ https://www.synabs.be/2025/07/01/lo-me-3-monoclonal-antibody-a-proven-tool-for-ige-detection-in-r-d-allergy-and-immunology-research/ https://www.synabs.be/2025/05/06/tackling-colistin-resistance-monoclonal-antibody-strategies-against-mcr-1/ https://www.synabs.be/2025/07/08/lo-mm-3-in-research-real-world-applications-in-immunology/ https://www.synabs.be/2025/04/29/advancing-vancomycin-b-resistance-detection-a-monoclonal-antibody-approach/ https://www.synabs.be/2025/04/23/targeting-estradiol-with-r-d-grade-monoclonal-antibodies-unlocking-the-potential-of-steroid-hormone-research/ https://www.synabs.be/2025/04/22/tackling-antibiotic-resistance-detection-of-vancomycin-a-with-monoclonal-antibodies/ https://www.synabs.be/2025/04/16/ccr10-targeting-with-monoclonal-antibodies-unlocking-new-frontiers-in-immunology-inflammation-and-oncology/ https://www.synabs.be/2025/04/15/the-added-value-of-mouse-and-rat-isotype-controls-in-research/ https://www.synabs.be/2025/04/10/valproic-acid-clinical-relevance-and-the-role-of-monoclonal-antibodies-in-accurate-measurement/ https://www.synabs.be/2025/04/10/androstenedione-as-a-diagnostic-marker-clinical-significance-and-immunological-challenges-in-antibody-specificity/ https://www.synabs.be/2025/03/11/synabs-expands-global-impact-in-hemoglobin-diagnostics-during-belgian-economic-mission-to-india/ https://www.synabs.be/2024/10/02/understanding-radioimmunotherapy-a-breakthrough-in-cancer-treatment/ https://www.synabs.be/2024/01/25/ccr8-targeting-a-promising-strategy-for-cancer-immunotherapy-and-beyond/ https://www.synabs.be/2023/09/19/unlocking-the-potential-of-synabs-monoclonal-antibodies-against-mmp-9/ https://www.synabs.be/2020/10/26/il-1%CE%B2-monoclonal-antibodies/ https://www.synabs.be/2023/06/15/lo-mm-synabs-rat-anti-igm-mouse-monoclonals/ https://www.synabs.be/2023/04/24/enhancing-crp-protein-detection-with-monoclonal-antibodies-a-breakthrough-in-inflammatory-disease-diagnostics/ https://www.synabs.be/2023/04/01/unravel-the-epigenetic-code-unlocking-the-secrets-of-histone-modifications-with-synabs-specific-monoclonal-antibodies/ https://www.synabs.be/2023/02/11/decoding-matrix-metalloproteases-mmp-a-journey-towards-effective-therapeutic-interventions/ https://www.synabs.be/2023/01/25/claudin-and-occludin-transmembrane-proteins-potential-of-cell-cell-tight-junctions-as-therapeutic-targets/ https://www.synabs.be/2022/11/25/synabs-announces-a-large-european-grant-for-the-generation-of-therapeutic-antibodies-on-transmembrane-targets-and-highly-conserved-soluble-proteins/ https://www.synabs.be/2022/10/22/membrane-antibody-therapeutic-approach-to-ion-channelopathies/ https://www.synabs.be/2022/10/03/synabs-launches-unique-anti-glucagon-monoclonals/ https://www.synabs.be/2022/09/20/synabs-signs-a-research-agreement-with-domain-therapeutics-to-discover-therapeutic-antibodies-on-gpcrs/ https://www.synabs.be/2022/08/13/g-protein-coupled-endothelin-receptors-and-their-natural-and-therapeutic-ligands/ https://www.synabs.be/2022/07/12/glutamate-transporter-a-brief-history-of-excitatory-amino-acid-transmembrane-proteins/ https://www.synabs.be/2022/06/09/taca-promising-oncology-targets/ https://www.synabs.be/2022/04/30/therapeutic-trends-of-g-protein-coupled-receptor-as-antibody-drug-conjugates-candidates/ https://www.synabs.be/2022/04/05/cx3cr1-gpcr-cx3c-chemokine-receptor-1-cx3cr1-transmembrane-receptor-friend-or-foe/ https://www.synabs.be/2022/03/19/immuno-oncology-therapeutic-potential-of-adenosine-receptors-targeting-the-purinergic-pathway/ https://www.synabs.be/2022/03/05/mark-marl-synabs-mouse-anti-rat-light-chain-monoclonals/ https://www.synabs.be/2022/02/26/lo-mg-synabs-rat-anti-igg-mouse-monoclonals/ https://www.synabs.be/2022/02/06/the-therapeutic-challenges-of-receptor-tyrosine-kinases/ https://www.synabs.be/2022/01/21/the-enigmatic-subclass-antibody-syngular-products-from-synabs/ https://www.synabs.be/2022/01/13/synabs-innovative-monoclonal-antibodies-targeting-hemoglobinopathia-diseases/ https://www.synabs.be/2021/12/04/cd2-the-missed-opportunity-for-monoclonal-antibodies-treatments/ https://www.synabs.be/2021/10/30/the-end-of-animal-use-for-antibody-generation-in-europe-really/ https://www.synabs.be/2021/10/02/synabs-anti-cd25-therapeutic-monoclonal-antibody/ https://www.synabs.be/2021/09/11/c3a-and-c5a-anaphylatoxin-receptors-therapeutic-gpcr-targets-of-the-complement-system/ https://www.synabs.be/2021/08/30/therapeutic-targets-of-the-complement-system/ https://www.synabs.be/2021/08/21/monoclonal-antibodies-to-human-cd-cell-surface-antigens/ https://www.synabs.be/2021/08/14/orphan-gpcr-and-their-untapped-therapeutic-potential-the-next-wave-of-drug-targets/ https://www.synabs.be/2021/06/11/cc-chemokine-receptors-latest-news-on-beta-chemokine-receptors-therapeutics/ https://www.synabs.be/2021/06/10/chemokine-receptors-a-promising-gpcr-family-to-target/ https://www.synabs.be/2021/04/09/functional-antibodies-b-cell-depleting-antibodies/ https://www.synabs.be/2021/03/19/synabs-and-belgian-volition-ink-strategic-agreement-on-epigenetics/ https://www.synabs.be/2021/03/08/viral-envelope-proteins-targets-for-therapeutic-neutralizing-antibodies-nabs/ https://www.synabs.be/2021/02/20/anti-drug-antibody-generation-how-to-take-advantage-of-immunogenicity-and-effectively-monitor-your-therapeutic-drug/ https://www.synabs.be/2021/01/25/how-do-ion-channels-work/ https://www.synabs.be/2021/01/11/a-brief-history-of-ion-channels/ https://www.synabs.be/2020/12/14/how-does-gpcr-move-learn-the-dynamics-of-the-seven-pass-transmembrane-domain-receptors/ https://www.synabs.be/2020/11/28/unique-anti-dyhydrotestosterone-antibodies/ https://www.synabs.be/2020/11/14/immunoaffinity-chromatography-principles-and-tools-of-the-market/ https://www.synabs.be/2020/11/06/polyclonals-oligoclonals-alternatives-to-monoclonals/ https://www.synabs.be/2020/10/24/surrogate-antibodies-therapeutic-monoclonals-humans-mimicking-animals/ https://www.synabs.be/2020/10/17/glycobiology-days-of-future-past/ https://www.synabs.be/2020/10/06/trail-the-new-grail/ https://www.synabs.be/2020/10/06/hek293-when-the-virus-meets-the-cell/ https://www.synabs.be/2020/10/05/history-of-gpcr/ https://www.synabs.be/2020/09/28/kiaa1199-hybid-of-cemip-the-same-protein-for-a-diversity-of-biological-functions/ https://www.synabs.be/2020/09/23/keeping-up-with-the-serpins/ https://www.synabs.be/2020/08/10/microbiome-zero-to-one/ https://www.synabs.be/2020/08/03/cho-cell-line-a-60-year-old-story/ https://www.synabs.be/2020/07/17/cancer-bacteria-a-long-story-rising-from-the-ashes/ https://www.synabs.be/2020/07/01/il1rap-a-new-biomarker-of-interest-for-cancer-targeting/ https://www.synabs.be/2020/07/01/an-introduction-to-the-exosome-world/ https://www.synabs.be/2020/06/23/revealing-the-full-potential-of-adeno-associated-virus-thanks-to-molecular-biology/ https://www.synabs.be/2020/06/09/how-much-do-you-know-covid-19-proteins/ https://www.synabs.be/2020/05/25/patients-immune-battle-against-covid-19/ https://www.synabs.be/2020/05/05/latest-news-on-covid/ https://www.synabs.be/2020/04/03/immune-response-to-coronavirus-infection/ https://www.synabs.be/2020/03/31/11-strategies-to-treat-coronavirus-you-should-know/ https://www.synabs.be/2020/03/17/bispecific-antibody-the-janus-god-of-therapeutics/ https://www.synabs.be/2020/02/25/the-future-of-therapeutic-antibodies-development/ https://www.synabs.be/2020/02/19/more-human-than-human-is-our-motto/ https://www.synabs.be/2020/02/14/anta-block-neutra-but-who-are-they/ https://www.synabs.be/2020/02/10/in-gut-we-trust/ https://www.synabs.be/2020/02/04/not-one-but-two-sizes-do-fit-all/ https://www.synabs.be/2020/01/30/the-dark-side-of-car-t-theray/ https://www.synabs.be/2020/01/16/in-accordance-with-fda-recommendations-can-a-biotinylated-mab-be-replaced-by-a-dnp-marked-mab/ https://www.synabs.be/2019/12/05/lo-hg4-anti-human-igg4-monoclonal-antibody-new-syngular-product-from-synabs/ https://www.synabs.be/2019/11/25/hybridoma-vs-display-the-fight-of-the-century/ https://www.synabs.be/2019/11/14/mycotoxin-the-reign-of-terror/ https://www.synabs.be/2019/10/18/are-you-sure-you-know-the-rat/ https://www.synabs.be/2019/09/25/three-letters-you-should-be-aware-of/ https://www.synabs.be/2019/09/18/answers-to-questions-on-secondary-antibodies/ https://www.synabs.be/2019/09/16/your-dna-isn-t-your-destiny-news-on-epigenetics/ https://www.synabs.be/2019/07/02/mabexperts-commits-to-the-future-of-immunotherapy-complete-vhh-car-t-design/ https://www.synabs.be/2019/06/26/best-tips-to-select-an-outsourcing-provider-for-custom-antibody-generation/ https://www.synabs.be/2019/06/10/unique-anti-vhh-monoclonal-antibodies-synabs-enters-into-the-nano-world/ https://www.synabs.be/2019/04/27/the-cam-family-a-new-target-for-monitoring-or-treating-cancers/ https://www.synabs.be/2019/04/20/synabs-and-univercells-announce-strategic-agreement-on-biosimilar/ https://www.synabs.be/2019/04/16/why-dna-immunization-is-still-necessary/ https://www.synabs.be/2019/04/12/replacing-in-vivo-by-an-in-vitro-test-rabies-mab-example/ https://www.synabs.be/2019/03/11/neurogenic-and-synabs-deal-for-schizophrenia-detection/ https://www.synabs.be/2019/01/28/horiba-synabs-partnership-production-of-a-rescued-recombinant-monoclonal-antibody-directed-against-a-steroid-hormone-and-its-binding-study-thanks-to-surface-plasmon-resonance-imaging-technology/ https://www.synabs.be/2017/12/14/synabs-rd-biotech-unique-expertise-in-car-t-cells/ https://www.synabs.be/2016/08/03/the-small-molecule-detection-challenge-the-aflatoxin-case-study/ https://www.synabs.be/about/